Calithera Biosciences, Inc. (CALA): Marketing Mix Analysis [Dec-2025 Updated]

You're looking at a company that's essentially a legal entity winding down, not a drug developer, which completely flips the script on its marketing mix. Honestly, when a firm like Calithera Biosciences, Inc. is in Chapter 11 and heading for dissolution, the 4 Ps aren't about selling medicine anymore; they're about liquidating residual Intellectual Property (IP) and managing creditor claims. As of late 2025, the stock is trading for pennies-about $0.0010 per share, leaving the market cap at a mere $4.87K-and the primary 'product' is the legal framework for asset sales, not a clinical candidate. If you want to see how the 'Price' is effectively zero for common holders against a projected -$10.48 million loss for the 2025 fiscal year, dive into the breakdown below; it's a masterclass in corporate shell economics, definetly worth a look.

Calithera Biosciences, Inc. (CALA) - Marketing Mix: Product

The product element for Calithera Biosciences, Inc. as of late 2025 is not a commercialized therapeutic but rather the residual value embedded within its corporate shell and liquidated assets, primarily intellectual property (IP) and former drug candidates.

The primary product is the monetization of these non-core assets, a process dictated by the Plan of Complete Liquidation and Dissolution approved in January 2023. The operational revenue for the 2025 fiscal year is reported as $0.00, a direct reflection of the company's non-operational, wind-down status. The last reported annual revenue from its operational period was $9.75 million as of December 31, 2021.

The current market valuation of this 'product' is negligible, with the market capitalization reported around $4,872.00 as of November 2025, and the stock trading at approximately $0.0010 per share.

Former Clinical-Stage Drug Candidates and Asset Sales

The core of the residual product value lies in the disposition of former clinical-stage assets. The monetization strategy involved the sale or divestiture of these compounds and their associated IP rights to maximize recovery for creditors.

For Telaglenastat (CB-839), the recommended Phase 2 dose (RP2D) was defined at 800 mg twice-daily, achieving over 90% GLS inhibition in platelets at plasma exposures greater than 300 nmol/L.

Remaining Intellectual Property (IP) Portfolio

The remaining IP portfolio is largely tied to the divested assets, but historical patent data provides context on the original scope of the research. The IP portfolio for the tumor metabolism program, which included CB-839, previously consisted of one issued U.S. patent directed to composition of matter for CB-839, which is set to expire in 2032.

The IP disposition is part of the asset monetization process.

• Issued U.S. Patent for CB-839: Expires in 2032.
• Pending U.S. Patent Applications (related to CB-839 and compounds): 6.
• Corresponding Pending PCT and Foreign Patent Applications: 17.

Licensed Assets Subject to Review and Corporate Shell Status

The product also encompasses residual financial claims or potential future milestone payments from prior agreements. Calithera Biosciences, Inc. had collaborations with entities including Incyte and Pfizer.

The corporate shell itself is an asset being managed for the orderly wind-down, with a small remaining team of 9 employees focused on administrative and legal compliance.

The financial structure supporting this wind-down shows a projected net loss for the 2025 fiscal year of approximately -$10.48 million. In April 2023, the company repurchased all outstanding Series A convertible preferred stock for $4.0 million in cash. The company expects its existing capital resources, combined with net proceeds from asset sales, to cover remaining liabilities and obligations, with no anticipated liquidating distributions to common stockholders.

Calithera Biosciences, Inc. (CALA) - Marketing Mix: Place

You're looking at the distribution strategy for Calithera Biosciences, Inc. as of late 2025. For a company in active liquidation, the traditional concept of 'Place' shifts entirely from product delivery to the distribution of remaining legal and financial assets. The primary channels are now the courts and the over-the-counter market for its residual equity.

Over-The-Counter (OTC) Markets Stock Exchange for Common Stock (OTCPK: CALA)

The common stock of Calithera Biosciences, Inc. is distributed via the Over-The-Counter (OTC) Markets, specifically under the ticker CALA on the OTCPK tier. This represents the final, albeit highly distressed, point of market access for residual security holders.

• Stock Price as of November 11, 2025: $0.001 USD.
• Market Capitalization as of November 2025: $4.87K.
• Trailing Twelve Months (TTM) Earnings Per Share (EPS): -7.94.
• Number of Employees as of November 2025: 9.

Delaware Chancery Court and US Bankruptcy Court for Chapter 11 Proceedings

The core 'Place' of operation for Calithera Biosciences, Inc. is the legal venue overseeing its wind-down. The distribution of any remaining value is dictated by the courts, not by commercial sales channels. The Chapter 11 bankruptcy proceedings began on November 6, 2023.

The legal framework dictates the order of priority for asset distribution to creditors and, potentially, shareholders. The proceedings are managed through the US Bankruptcy Court, with underlying corporate governance matters often addressed in the Delaware Chancery Court.

Legal and Financial Channels for Asset Sales to Other Biopharma Companies

The actual distribution of the company's intellectual property and drug candidates-the former 'products'-occurs through legal and financial channels, primarily asset sales or acquisitions approved by the Bankruptcy Court. A concrete example of this channel in action, though preceding the formal Chapter 11 filing, involved an asset transaction.

The focus remains on asset liquidation to satisfy creditor claims, a process managed entirely within the court's jurisdiction.

South San Francisco, California, as the Former Corporate Headquarters Location

The physical location, which served as the former distribution nexus for corporate functions, is now a historical data point. The corporate office was located at 343 Oyster Point Boulevard; Suite 200; South San Francisco, CA 94080. This location was the center of operations before the company shifted its focus to dissolution.

The Distribution Channel is the Legal Framework of the Dissolution Plan

The ultimate 'Place' strategy is the court-approved dissolution plan itself. This legal framework dictates how the remaining corporate shell and any unliquidated assets are distributed. The company is no longer focused on market penetration but on legal closure.

Here are key financial markers related to the operational end-state, which informs the asset distribution:

• Last Reported Full-Year Revenue (FY 2022): $28.53m.
• Gross Profit (FY 2022): $-7.2m.
• Total Earnings/Net Loss (FY 2022): $-21.3m.
• Chapter 11 Initiation Date: November 6, 2023.
• Next Scheduled Financial Report Date (Estimate): November 27, 2025.

The distribution channel is the court order. Finance: finalize the creditor claim reconciliation schedule by EOD Tuesday.

Calithera Biosciences, Inc. (CALA) - Marketing Mix: Promotion

You're looking at the promotional strategy for Calithera Biosciences, Inc. as of late 2025, which is essentially a communication strategy focused on corporate wind-down and legal compliance, not product sales. The promotional mix has collapsed into mandatory disclosures.

Required public filings with the SEC regarding the liquidation process centered on the formal steps of ceasing operations. The Board of Directors unanimously approved the dissolution and liquidation pursuant to a Plan of Complete Liquidation and Dissolution on January 9, 2023. Trading of the common stock was suspended on February 2, 2023, following written notice from Nasdaq on January 24, 2023, that the company was a "public shell". The company intended to file a Certificate of Dissolution with the Delaware Secretary of State upon stockholder approval.

Investor relations communication, managed through contact Stephanie Wong, primarily addressed the failure to execute the planned dissolution timeline. The Special Meeting of stockholders, intended for June 29, 2023, to approve the Plan of Dissolution, was cancelled because the company could not achieve a quorum.

The structure of remaining financial obligations and potential distributions dictated the nature of creditor and partner communication. The initial plan involved satisfying all liabilities and establishing a reserve for future liquidation expenses.

The promotional focus is entirely on legal compliance and asset recovery updates, as operational marketing ceased. The company discontinued all clinical development programs and began reducing its workforce, including the termination of most employees by the end of the first quarter of 2023.

Here's a look at the key financial context underpinning these mandatory communications as of late 2025:

The communication activities, though minimal, were directed toward specific compliance and recovery milestones:

• Filing of proxy materials with the SEC regarding the Plan of Dissolution.
• Notification of delisting from The Nasdaq Global Select Market effective February 2, 2023.
• Communication regarding the inability to achieve quorum on June 29, 2023.
• Expectation that remaining assets will cover liabilities and preferred stock obligations, with no anticipated liquidating distributions to common stockholders.
• The company is trading over-the-counter (OTCPK: CALA).

The potential distribution to common stockholders, had the Plan of Dissolution been approved, was estimated at approximately $2.0 million based on shares outstanding as of May 1, 2023. Finance: draft final asset recovery status report by next Tuesday.

Calithera Biosciences, Inc. (CALA) - Marketing Mix: Price

Price, in the context of Calithera Biosciences, Inc. (CALA), is less about setting a competitive price for a product and more about the market valuation of the remaining equity as the company executes its wind-down plan. The pricing strategy here is entirely dictated by the market's perception of residual asset value versus outstanding liabilities, given the company is operating under a Plan of Complete Liquidation and Dissolution.

The market's valuation of the common stock reflects this distressed situation. Common stock is trading at a distressed price of approximately $0.0010 per share as of November 2025. This low price point is a direct consequence of the company's operational status and the priority of claims against its assets.

The resulting market capitalization is negligible, reported at only $4.87K as of November 2025, based on the shares outstanding noted in prior filings. To put this in perspective against the company's financial performance, here's a look at the scale of operations and losses:

The pricing mechanism for the equity is fundamentally tied to the liquidation process. Operational revenue for the 2025 fiscal year is effectively zero, which is expected for a company winding down operations. This lack of incoming cash flow means the equity value is entirely dependent on asset realization.

The financial burden remains significant, as evidenced by the losses incurred during the wind-down phase. The estimated net loss for the 2025 fiscal year was projected around -$10.48 million, though trailing twelve-month figures show a net income of -$21.29 million. The latest reported quarterly net income was -$6.94 million. This ongoing burn rate impacts the final recoverable value for shareholders.

Regarding distributions, the primary factor influencing the price is the hierarchy of claims. No liquidating distributions are anticipated for common stock holders due to liabilities, as the liquidation preference of prior preferred shares historically took precedence. However, there was a contingent plan discussed:

• Potential distribution of $0.40 per share to common stockholders.
• This was contingent upon shareholder approval of the Plan of Dissolution.
• The distribution would occur prior to any further distribution to Takeda Ventures.
• Approximately $2.0 million was estimated for common stockholders based on May 1, 2023, share count.

If the Plan of Dissolution is not approved, the company will not make any liquidating distribution to common stockholders. The current trading price of $0.0010 reflects the market's assessment of the probability of realizing any value above the liabilities and preferred claims, which, as stated, is currently expected to be none.